ReviewActas espanolas de psiquiatria2025
Critical Overview of Screening Tools for Detecting Bipolar Disorders.
Review in Actas espanolas de psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This overview aims to explore the key screening tools for detecting bipolar disorders (BDs): the Mood Disorder Questionnaire (MDQ), Bipolar Spectrum Diagnostic Scale (BSDS), Hypomania Checklist (HCL-32), and Rapid Mood Screener (RMS), while offering guidance to healthcare professionals in selecting the most appropriate tool for each clinical scenario. The MDQ is widely utilized due to its high specificity (0.90) for identifying Bipolar Disorder (BD) in psychiatric consultations, although it is more sensitive to bipolar I than bipolar II. The BSDS, designed to encompass a wider range of bipolar spectrum symptoms, exhibits a sensitivity of 0.70 and specificity of 0.89, which makes it a complementary tool to the MDQ. The HCL-32 concentrates on detecting hypomanic traits in Major Depressive Disorder (MDD) patients, showing good sensitivity (80%) but lower specificity (51%). It is particularly effective for distinguishing BD from unipolar depression, although it cannot differentiate between Bipolar Disorder type I (BDI) and Bipolar Disorder type II (BDII). The RMS is a newer tool that quickly screens for manic symptoms and risk factors, boasting a sensitivity of 0.88 and a specificity of 0.80. Together, these screening instruments facilitate the early identification of BDs, though positive results should always be followed by a thorough clinical evaluation. Employing multiple tools simultaneously can improve diagnostic accuracy and more effectively capture the diverse presentations of BDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.